- Home
- STLA vs ARGX Comparison
STLA vs ARGX Comparison
Compare STLA & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STLA
- ARGX
- Stock Information
- Founded
- STLA 2021
- ARGX 2008
- Country
- STLA Netherlands
- ARGX Netherlands
- Employees
- STLA N/A
- ARGX N/A
- Industry
- STLA Auto Manufacturing
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STLA Consumer Discretionary
- ARGX Health Care
- Exchange
- STLA Nasdaq
- ARGX Nasdaq
- Market Cap
- STLA 36.7B
- ARGX 40.4B
- IPO Year
- STLA N/A
- ARGX 2017
- Fundamental
- Price
- STLA $11.10
- ARGX $572.52
- Analyst Decision
- STLA Hold
- ARGX Strong Buy
- Analyst Count
- STLA 9
- ARGX 20
- Target Price
- STLA $20.84
- ARGX $682.00
- AVG Volume (30 Days)
- STLA 19.4M
- ARGX 325.0K
- Earning Date
- STLA 02-26-2025
- ARGX 05-08-2025
- Dividend Yield
- STLA 6.64%
- ARGX N/A
- EPS Growth
- STLA N/A
- ARGX N/A
- EPS
- STLA 1.90
- ARGX 12.78
- Revenue
- STLA $162,416,399,263.00
- ARGX $2,248,205,000.00
- Revenue This Year
- STLA $6.82
- ARGX $57.86
- Revenue Next Year
- STLA $4.78
- ARGX $31.90
- P/E Ratio
- STLA $5.82
- ARGX $43.01
- Revenue Growth
- STLA N/A
- ARGX 77.22
- 52 Week Low
- STLA $10.95
- ARGX $352.77
- 52 Week High
- STLA $27.72
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- STLA 32.40
- ARGX 43.11
- Support Level
- STLA $11.94
- ARGX $574.81
- Resistance Level
- STLA $12.51
- ARGX $598.06
- Average True Range (ATR)
- STLA 0.28
- ARGX 12.69
- MACD
- STLA -0.11
- ARGX -0.16
- Stochastic Oscillator
- STLA 8.33
- ARGX 36.55
About STLA Stellantis N.V.
Stellantis was created out of the merger of US-based Fiat Chrysler Automobiles, or FCA, and French-based Peugeot, or PSA, in January 2021, resulting in the fourth-largest automotive original equipment manufacturer, or OEM, by vehicle sales. In 2023 it sold 6.4 million vehicles, 44% and 30% in Europe and North America, respectively. North America is the most profitable region, contributing 53% of operating income. Its brands include Fiat, Jeep, Chrysler, Ram, Peugeot, Citroen, Opel, Alfa Romeo, and Maserati.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.